Noncontact detection of ocular melanoma with L-3-123I-iodo-alpha-methyltyrosine: first clinical results.
The results of the first clinical trial are presented of the newly designed tumor-seeking radiopharmaceutical L-3-123I-iodo-alpha-methyltyrosine (IMT) for noncontact detection of malignant eye melanoma by means of a nuclear medicine technique. Eye scintigraphy (ES) was performed on ten outpatients clinically suspected of harboring an intraocular melanoma. ES was carried out with a twin pinhole eye collimator attached to a high resolution gamma camera; 7-10 mCi of IMT was given intravenously to each patient 100-150 min prior to the nuclear medicine investigation. Gamma camera eye scintigraphy and the use of IMT offer a useful noninvasive alternative to the radiophosphorus uptake test. Of the ten patients, five were found not to have a melanoma either clinically or by scintigraphy, three had a melanoma by scintigraphy that was confirmed histologically, and two yielded inconclusive results.
D000368:Aged; D005134:Eye Neoplasms / Q000000981:diagnostic imaging*; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes; D007553:Isotope Labeling; D008297:Male; D008545:Melanoma / Q000000981:diagnostic imaging*; D008722:Methods; D008781:Methyltyrosines; D008875:Middle Aged; D011877:Radionuclide Imaging
D007457:Iodine Radioisotopes; D008781:Methyltyrosines; C030855:3-iodo-alpha-methyltyrosine